{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T07:31:13Z","timestamp":1786347073242,"version":"build-2736575974"},"reference-count":163,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Drug-induced liver injury (DILI) is an important drug-induced disease in clinical practice, with a complex pathogenesis and challenges in diagnosis and treatment. Glycyrrhizin preparations are a class of hepatoprotective agents derived from the traditional Chinese medicinal plant Glycyrrhiza uralensis, and have shown significant efficacy in the treatment of DILI due to their multi-target and multi-pathway pharmacological effects. Currently, they have been recommended as core therapeutic drugs for DILI in multiple domestic and international guidelines. This review delves into the advanced evidence-based medical evidence for the treatment of DILI with glycyrrhizin preparations and their recommended status in various guidelines. It also systematically expounds the precise treatment strategies of glycyrrhizin preparations based on DILI classification, severity, and special populations, and elaborately analyzes their cutting-edge mechanisms of action such as regulation of the gut-liver axis and epigenetic modifications. It discusses the challenges in clinical application, such as adverse reactions and predictive markers of efficacy, and their optimization solutions, and looks forward to future research directions. This article aims to promote the precise application of glycyrrhizin preparations in the treatment of DILI, providing practical diagnostic and therapeutic references for clinicians.<\/jats:p>","DOI":"10.3389\/fphar.2026.1890794","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T07:19:02Z","timestamp":1786346342000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Precision treatment and frontier advances of glycyrrhizin preparations in drug-induced liver injury (DILI)"],"prefix":"10.3389","volume":"17","author":[{"given":"Dianya","family":"Qiu","sequence":"first","affiliation":[{"name":"Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University","place":["Beijing, China"]},{"name":"Clinical Cure and Immunology Joint Laboratory for Clinical Medicine, HBV Infection, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixuan","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University","place":["Beijing, China"]},{"name":"Clinical Cure and Immunology Joint Laboratory for Clinical Medicine, HBV Infection, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University","place":["Beijing, China"]},{"name":"Clinical Cure and Immunology Joint Laboratory for Clinical Medicine, HBV Infection, Capital Medical University","place":["Beijing, China"]},{"name":"Department of Hepatology Division 2, Peking University Ditan Teaching Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyu","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University","place":["Beijing, China"]},{"name":"Clinical Cure and Immunology Joint Laboratory for Clinical Medicine, HBV Infection, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University","place":["Beijing, China"]},{"name":"Clinical Cure and Immunology Joint Laboratory for Clinical Medicine, HBV Infection, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University","place":["Beijing, China"]},{"name":"Clinical Cure and Immunology Joint Laboratory for Clinical Medicine, HBV Infection, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihua","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University","place":["Beijing, China"]},{"name":"Clinical Cure and Immunology Joint Laboratory for Clinical Medicine, HBV Infection, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University","place":["Beijing, China"]},{"name":"Clinical Cure and Immunology Joint Laboratory for Clinical Medicine, HBV Infection, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University","place":["Beijing, China"]},{"name":"Clinical Cure and Immunology Joint Laboratory for Clinical Medicine, HBV Infection, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University","place":["Beijing, China"]},{"name":"Clinical Cure and Immunology Joint Laboratory for Clinical Medicine, HBV Infection, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University","place":["Beijing, China"]},{"name":"Clinical Cure and Immunology Joint Laboratory for Clinical Medicine, HBV Infection, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linmei","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University","place":["Beijing, China"]},{"name":"Clinical Cure and Immunology Joint Laboratory for Clinical Medicine, HBV Infection, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuojie","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University","place":["Beijing, China"]},{"name":"Clinical Cure and Immunology Joint Laboratory for Clinical Medicine, HBV Infection, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyong","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University","place":["Beijing, China"]},{"name":"Clinical Cure and Immunology Joint Laboratory for Clinical Medicine, HBV Infection, Capital Medical University","place":["Beijing, China"]},{"name":"Department of Hepatology Division 2, Peking University Ditan Teaching Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University","place":["Beijing, China"]},{"name":"Clinical Cure and Immunology Joint Laboratory for Clinical Medicine, HBV Infection, Capital Medical University","place":["Beijing, China"]},{"name":"Department of Hepatology Division 2, Peking University Ditan Teaching Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghui","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University","place":["Beijing, China"]},{"name":"Clinical Cure and Immunology Joint Laboratory for Clinical Medicine, HBV Infection, Capital Medical University","place":["Beijing, China"]},{"name":"Department of Hepatology Division 2, Peking University Ditan Teaching Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"385","DOI":"10.4196\/kjpp.2021.25.5.385","article-title":"Loss of RAR-\u03b1 and RXR-\u03b1 and enhanced Caspase-3-Dependent apoptosis in N-Acetyl-p-Aminophenol-Induced liver injury in mice is tissue factor dependent","volume":"25","author":"Abdel-Bakky","year":"2021","journal-title":"Korean J. Physiol. Pharmacol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.cld.2016.08.004","article-title":"Epidemiology and genetic risk factors of drug hepatotoxicity","volume":"21","author":"Ahmad","year":"2017","journal-title":"Clin. Liver Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jhep.2019.10.003","article-title":"The gut-liver axis in liver disease: pathophysiological basis for therapy","volume":"72","author":"Albillos","year":"2020","journal-title":"J. Hepatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1080\/10937404.2023.2261848","article-title":"Drug induced liver injury - a 2023 update","volume":"26","author":"Allison","year":"2023","journal-title":"J. Toxicol. Environ. Health B Crit. Rev."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e151","DOI":"10.4158\/EP14094.CR","article-title":"Apparent mineralocorticoid excess caused by a novel mutation in 11-\u03b2 hydroxysteroid dehydrogenase type 2 enzyme: its genetics and response to therapy","volume":"20","author":"Alzahrani","year":"2014","journal-title":"Endocr. Pract."},{"key":"B6","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-019-0105-0","article-title":"Drug-Induced Liver Injury","volume":"5","author":"Andrade","year":"2019","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B7","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/nature12726","article-title":"Metabolites produced by commensal bacteria promote peripheral regulatory T-Cell generation","volume":"504","author":"Arpaia","year":"2013","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jaip.2023.09.011","article-title":"Vancomycin-Induced liver injury, DRESS, and HLA-A\u221732:01","volume":"12","author":"Asif","year":"2024","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B9","first-page":"844","article-title":"Expert Committee on Clinical Application of Glycyrrhizin Preparation in the Treatment of Liver Diseases Expert consensus on the clinical application of glycyrrhizic acid preparations in liver diseases [in Chinese]","volume":"32","author":"Author Anonymous","year":"2016","journal-title":"J. Clin. Hepatology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s00228-012-1429-9","article-title":"NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-Month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy","volume":"69","author":"Azuma","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/0168-8278(90)90124-a","article-title":"Criteria of drug-induced liver disorders. Report of an international consensus meeting","volume":"11","author":"B\u00e9nichou","year":"1990","journal-title":"J. Hepatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1055\/s-0044-1779520","article-title":"UDCA for drug-induced liver disease: clinical and pathophysiological basis","volume":"44","author":"Bessone","year":"2024","journal-title":"Semin. Liver Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"162","DOI":"10.14218\/JCTH.2024.00325","article-title":"Ursodeoxycholic acid for the management of drug-induced liver injury: role of hepatoprotective and anti-cholestatic mechanisms","volume":"13","author":"Bessone","year":"2025","journal-title":"J. Clin. Transl. Hepatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1142\/S0192415X23500209","article-title":"Efficacy and safety of glycyrrhizic acid in treatment of autoimmune hepatitis","volume":"51","author":"Bi","year":"2023","journal-title":"Am. J. Chin. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.16439\/j.issn.1673-7245.2024.11.017","article-title":"Case of pseudohyperaldosteronism induced by compound glycyrrhizin","volume":"32","author":"Bi","year":"2024","journal-title":"Chin. J. Hypertens."},{"key":"B16","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/ueg2.12113","article-title":"Clinical management of patients with drug-induced liver injury (DILI)","volume":"9","author":"Bj\u00f6rnsson","year":"2021","journal-title":"United Eur. Gastroenterol. J."},{"key":"B17","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1631\/jzus.B2100977","article-title":"Molecular pathogenesis of acetaminophen-induced liver injury and its treatment options","volume":"23","author":"Cai","year":"2022","journal-title":"J. Zhejiang Univ. Sci. B"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.2337\/db06-1491","article-title":"Metabolic endotoxemia initiates obesity and insulin resistance","volume":"56","author":"Cani","year":"2007","journal-title":"Diabetes"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e397","DOI":"10.5546\/aap.2017.eng.e397","article-title":"Herb- and dietary supplement-induced liver injury","volume":"115","author":"Cavalieri","year":"2017","journal-title":"Arch. Argent. Pediatr."},{"key":"B20","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.bsheal.2023.01.002","article-title":"Towards precision medicine: omics approach for COVID-19","volume":"5","author":"Cen","year":"2023","journal-title":"Biosaf. Health"},{"key":"B21","doi-asserted-by":"publisher","first-page":"878","DOI":"10.14309\/ajg.0000000000001259","article-title":"Practice parameters committee of the American college of gastroenterology ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury","volume":"116","author":"Chalasani","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1152\/physrev.00020.2012","article-title":"11\u03b2-Hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action","volume":"93","author":"Chapman","year":"2013","journal-title":"Physiol. Rev."},{"key":"B23","doi-asserted-by":"publisher","first-page":"223","DOI":"10.15932\/j.0253-9713.2014.03.012","article-title":"Efficacy analysis of magnesium isoglycyrrhizinate injection in the treatment of anti-tuberculosis drug-induced acute liver injury [in Chinese]","volume":"36","author":"Chen","year":"2014","journal-title":"Beijing Med. J."},{"key":"B24","doi-asserted-by":"publisher","first-page":"3869698","DOI":"10.1155\/2020\/3869698","article-title":"Meta-analysis based on clinical RCTs: the effect of molecular epimerism on the safety of glycyrrhizic acid","volume":"2020","author":"Chen","year":"2020","journal-title":"Evid. Based Complement. Altern. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"688780","DOI":"10.3389\/fphys.2021.688780","article-title":"Gut microbiota and chemical-induced acute liver injury","volume":"12","author":"Chen","year":"2021","journal-title":"Front. Physiol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"173258","DOI":"10.1016\/j.ejphar.2020.173258","article-title":"Combination of monoammonium glycyrrhizinate and cysteine hydrochloride ameliorated Lipopolysaccharide\/Galactosamine-Induced acute liver injury through Nrf2\/ARE pathway","volume":"882","author":"Chu","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.hbpd.2023.06.008","article-title":"Contribution of gut microbiota to drug-induced liver injury","volume":"22","author":"Chu","year":"2023","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.3390\/genes15101313","article-title":"Role of circulating microRNAs in liver disease and HCC: focus on miR-122","volume":"15","author":"Colaianni","year":"2024","journal-title":"Genes (Basel)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.19405\/j.cnki.issn1000-1492.2023.08.021","article-title":"Xiaoguo Protective effect of glycyrrhizic acid-mediated miRNAs on alcoholic liver injury in rats [in Chinese]","volume":"58","author":"Cong","year":"2023","journal-title":"Acta Univ. Med. Anhui"},{"key":"B30","doi-asserted-by":"publisher","first-page":"611913","DOI":"10.3389\/fmedt.2020.611913","article-title":"Current perspective: 3D spheroid models utilizing human-based cells for investigating metabolism-dependent drug-induced liver injury","volume":"2","author":"Cox","year":"2020","journal-title":"Front. Med. Technol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/ng.379","article-title":"HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin","volume":"41","author":"Daly","year":"2009","journal-title":"Nat. Genet."},{"key":"B32","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/ijms17010014","article-title":"RUCAM in drug and herb induced liver injury: the update","volume":"17","author":"Danan","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1002\/jcb.24822","article-title":"MicroRNA-122 overexpression promotes hepatic differentiation of human adipose tissue-derived stem cells","volume":"115","author":"Davoodian","year":"2014","journal-title":"J. Cell Biochem."},{"key":"B34","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1007\/s12072-021-10144-3","article-title":"Drug-Induced liver Injury: Asia Pacific association of study of liver consensus guidelines","volume":"15","author":"Devarbhavi","year":"2021","journal-title":"Hepatol. Int."},{"key":"B35","first-page":"66","article-title":"Clinical efficacy analysis of magnesium isoglycyrrhizinate in the treatment of novel anti-tumor drug-related drug-induced liver injury","volume-title":"Proceedings of the Proceedings of the 12th National Conference on Difficult and Severe Liver Diseases","author":"Duan","year":"2023"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","volume":"70","year":"2019","journal-title":"J. Hepatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"9","DOI":"10.15887\/j.cnki.13-1389\/r.2025.25.003","article-title":"Clinical efficacy of magnesium isoglycyrrhizinate in preventing chemotherapy-induced drug-related liver injury [in Chinese]","volume":"18","author":"Fan","year":"2025","journal-title":"Clin. Ration. Drug Use"},{"key":"B38","doi-asserted-by":"publisher","first-page":"9988167","DOI":"10.1155\/2024\/9988167","article-title":"Exploring the role of licorice and its derivatives in cell signaling pathway NF-\u03baB and MAPK","volume":"2024","author":"Fatima","year":"2024","journal-title":"J. Nutr. Metab."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1002\/hep.32689","article-title":"AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury","volume":"77","author":"Fontana","year":"2023","journal-title":"Hepatology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"4366","DOI":"10.1007\/s10528-024-10936-w","article-title":"Glycyrrhizic acid inhibits hippocampal neuron apoptosis by activating the PI3K\/AKT signaling pathway","volume":"63","author":"Fu","year":"2025","journal-title":"Biochem. Genet."},{"key":"B41","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/j.1348-0421.2000.tb02566.x","article-title":"Glycyrrhizin inhibits the lytic pathway of Complement--Possible mechanism of its anti-inflammatory effect on liver cells in viral hepatitis","volume":"44","author":"Fujisawa","year":"2000","journal-title":"Microbiol. Immunol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1136\/gutjnl-2024-333171","article-title":"British society of gastroenterology guidelines for diagnosis and management of autoimmune hepatitis","volume":"74","author":"Gleeson","year":"2025","journal-title":"Gut"},{"key":"B43","volume-title":"Evidence-Based Evaluation of Glycyrrhizic Acid Preparations in the Prevention and Treatment of ATB-DILI and Its Mechanism Based on Intestinal Flora [In Chinese]","author":"Gong","year":"2022"},{"key":"B44","doi-asserted-by":"publisher","first-page":"153942","DOI":"10.1016\/j.phymed.2022.153942","article-title":"Comparative effectiveness of glycyrrhizic acid preparations aimed at preventing and treating anti-tuberculosis drug-induced liver injury: a network meta-analysis of 97 randomized controlled trials","volume":"98","author":"Gong","year":"","journal-title":"Phytomedicine"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.3390\/ph15091130","article-title":"Magnesium isoglycyrrhizinate attenuates anti-tuberculosis drug-induced liver injury by enhancing intestinal barrier function and inhibiting the LPS\/TLRs\/NF-\u03baB signaling pathway in mice","volume":"15","author":"Gong","year":"","journal-title":"Pharm. (Basel)"},{"key":"B46","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1053\/j.gastro.2016.08.057","article-title":"An intestinal microbiota-farnesoid X receptor axis modulates metabolic disease","volume":"151","author":"Gonzalez","year":"2016","journal-title":"Gastroenterology"},{"key":"B47","doi-asserted-by":"publisher","first-page":"4865","DOI":"10.3748\/wjg.15.4865","article-title":"Biochemical mechanisms in drug-induced liver injury: certainties and doubts","volume":"15","author":"Grattagliano","year":"2009","journal-title":"World J. Gastroenterol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"116430","DOI":"10.1016\/j.ecoenv.2024.116430","article-title":"Cu exposure induces liver inflammation via regulating gut Microbiota\/LPS\/Liver TLR4 signaling axis","volume":"278","author":"Gu","year":"2024","journal-title":"Ecotoxicol. Environ. Saf."},{"key":"B49","doi-asserted-by":"publisher","first-page":"10556","DOI":"10.1074\/jbc.M411673200","article-title":"Licorice compounds glycyrrhizin and 18beta-Glycyrrhetinic acid are potent modulators of bile acid-induced cytotoxicity in rat hepatocytes","volume":"280","author":"Gumpricht","year":"2005","journal-title":"J. Biol. Chem."},{"key":"B50","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.3748\/wjg.v19.i24.3781","article-title":"Glycyrrhizic acid attenuates CCl4-Induced hepatocyte apoptosis in rats via a P53-Mediated pathway","volume":"19","author":"Guo","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"154587","DOI":"10.1016\/j.phymed.2022.154587","article-title":"Glycyrrhizic acid alleviates liver fibrosis in vitro and in vivo via activating CUGBP1-Mediated IFN-\u03b3\/STAT1\/Smad7 pathway","volume":"112","author":"Guo","year":"2023","journal-title":"Phytomedicine"},{"key":"B52","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1189\/jlb.0112038","article-title":"Glycyrrhizin and isoliquiritigenin suppress the LPS sensor toll-like receptor 4\/MD-2 complex signaling in a different manner","volume":"91","author":"Honda","year":"2012","journal-title":"J. Leukoc. Biol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"17562848231163410","DOI":"10.1177\/17562848231163410","article-title":"Drug-Induced liver injury: a comprehensive review","volume":"16","author":"Hosack","year":"2023","journal-title":"Ther. Adv. Gastroenterol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1111\/jcmm.17149","article-title":"Glycyrrhizin regulates rat TMJOA progression by inhibiting the HMGB1-RAGE\/TLR4-NF-\u03baB\/AKT pathway","volume":"26","author":"Hu","year":"2022","journal-title":"J. Cell Mol. Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jcma.2014.01.010","article-title":"Recent progress in genetic variation and risk of antituberculosis drug-induced liver injury","volume":"77","author":"Huang","year":"2014","journal-title":"J. Chin. Med. Assoc."},{"key":"B56","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1080\/15563650.2023.2259089","article-title":"Novel biomarkers for drug-induced liver injury","volume":"61","author":"Humphries","year":"2023","journal-title":"Clin. Toxicol. (Phila)"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1248\/bpb.b20-00424","article-title":"Risk factors for pseudoaldosteronism with yokukansan use: analysis using the Japanese adverse drug report (JADER) database","volume":"43","author":"Ishida","year":"2020","journal-title":"Biol. Pharm. Bull."},{"key":"B58","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1248\/bpb.23.904","article-title":"Determination of serum concentrations of glycyrrhizin in humans by semi-micro high-performance liquid chromatography after administration of a therapeutic dose","volume":"23","author":"Ishiwata","year":"2000","journal-title":"Biol. Pharm. Bull."},{"key":"B59","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3109\/03602532.2011.602688","article-title":"Oxidant stress, mitochondria, and cell death mechanisms in drug-induced liver injury: lessons learned from acetaminophen hepatotoxicity","volume":"44","author":"Jaeschke","year":"2012","journal-title":"Drug Metab. Rev."},{"key":"B60","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1016\/j.csbj.2021.04.029","article-title":"Farnesoid X receptor (FXR): structures and ligands","volume":"19","author":"Jiang","year":"2021","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"B61","doi-asserted-by":"publisher","first-page":"134319","DOI":"10.1016\/j.jhazmat.2024.134319","article-title":"18\u03b2-Glycyrrhetinic acid protects against deoxynivalenol-induced liver injury via modulating ferritinophagy and mitochondrial quality control","volume":"471","author":"Jiang","year":"2024","journal-title":"J. Hazard Mater"},{"key":"B62","first-page":"119","article-title":"Therapeutic effect observation of magnesium isoglycyrrhizinate on drug-induced liver injury in the elderly [in Chinese]","volume":"29","author":"Jin","year":"2015","journal-title":"Pract. Geriatr."},{"key":"B63","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nrd1750","article-title":"Idiosyncratic drug hepatotoxicity","volume":"4","author":"Kaplowitz","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"B64","doi-asserted-by":"publisher","first-page":"s104","DOI":"10.7861\/clinmedicine.16-6-s104","article-title":"Drug-Induced liver injury","volume":"16","author":"Katarey","year":"2016","journal-title":"Clin. Med. (Lond)"},{"key":"B65","doi-asserted-by":"publisher","first-page":"500","DOI":"10.3803\/EnM.2016.31.4.500","article-title":"Bile acid nuclear receptor farnesoid X receptor: therapeutic target for nonalcoholic fatty liver disease","volume":"31","author":"Kim","year":"2016","journal-title":"Endocrinol. Metab. Seoul."},{"key":"B66","doi-asserted-by":"publisher","first-page":"5266","DOI":"10.3390\/ijms20215266","article-title":"The crosstalk of miRNA and oxidative stress in the liver: from physiology to pathology and clinical implications","volume":"20","author":"Klieser","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B67","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.1007\/s00204-021-03121-0","article-title":"The application of Cytokeratin-18 as a biomarker for drug-induced liver injury","volume":"95","author":"Korver","year":"2021","journal-title":"Arch. Toxicol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/toxsci\/kfab069","article-title":"Analytical and omics-based advances in the study of drug-induced liver injury","volume":"183","author":"Kralj","year":"2021","journal-title":"Toxicol. Sci."},{"key":"B69","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1111\/j.1472-8206.2008.00608.x","article-title":"Drug-Induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies","volume":"22","author":"Labbe","year":"2008","journal-title":"Fundam. Clin. Pharmacol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1056\/NEJMra021844","article-title":"Drug-Induced hepatotoxicity","volume":"349","author":"Lee","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"B71","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ymeth.2020.06.022","article-title":"Modern epigenetics methods in biological research","volume":"187","author":"Li","year":"2021","journal-title":"Methods"},{"key":"B72","doi-asserted-by":"publisher","first-page":"872139","DOI":"10.1155\/2014\/872139","article-title":"Glycyrrhizic acid in the treatment of liver diseases: literature review","volume":"2014","author":"Li","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"B73","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/S1875-5364(16)30063-2","article-title":"Effects of diammonium glycyrrhizinate on hepatic and intestinal UDP-Glucuronosyltransferases in rats: implication in herb-drug interactions","volume":"14","author":"Li","year":"2016","journal-title":"Chin. J. Nat. Med."},{"key":"B74","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1007\/s00223-018-0425-1","article-title":"Glycyrrhizin suppresses RANKL-Induced osteoclastogenesis and oxidative stress through inhibiting NF-\u03baB and MAPK and activating AMPK\/Nrf2","volume":"103","author":"Li","year":"2018","journal-title":"Calcif. Tissue Int."},{"key":"B75","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.phrs.2019.04.025","article-title":"Natural products in licorice for the therapy of liver diseases: progress and future opportunities","volume":"144","author":"Li","year":"","journal-title":"Pharmacol. Res."},{"key":"B76","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1002\/hep.30660","article-title":"HLA-B*35:01 allele is a potential biomarker for predicting polygonum Multiflorum-Induced liver injury in humans","volume":"70","author":"Li","year":"","journal-title":"Hepatology"},{"key":"B77","doi-asserted-by":"publisher","first-page":"806249","DOI":"10.3389\/fphar.2021.806249","article-title":"Pharmacotherapies for drug-induced liver injury: a current literature review","volume":"12","author":"Li","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"101355","DOI":"10.1016\/j.jcmgh.2024.05.003","article-title":"Interplay between drug-induced liver injury and gut microbiota: a comprehensive overview","volume":"18","author":"Li","year":"2024","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"5271","DOI":"10.3748\/wjg.v21.i17.5271","article-title":"Glycyrrhizic acid inhibits apoptosis and fibrosis in carbon-tetrachloride-induced rat liver injury","volume":"21","author":"Liang","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"B80","first-page":"3150","article-title":"Research progress on the anti-hepatocellular carcinoma mechanism of glycyrrhetinic acid and its application as a liver-targeting ligand","volume":"28","author":"Liang","year":"2017","journal-title":"China Pharm."},{"key":"B81","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1080\/17425255.2020.1758060","article-title":"Lipid and purine metabolism involved in hepatotoxicity of first-line anti-tuberculosis drugs","volume":"16","author":"Liu","year":"2020","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"723940","DOI":"10.3389\/fphar.2021.723940","article-title":"The immunological mechanisms and immune-based biomarkers of drug-induced liver injury","volume":"12","author":"Liu","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s10020-019-0085-2","article-title":"miR-122 promotes hepatic lipogenesis via inhibiting the LKB1\/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease","volume":"25","author":"Long","year":"2019","journal-title":"Mol. Med."},{"key":"B84","doi-asserted-by":"publisher","first-page":"911","DOI":"10.4254\/wjh.v10.i12.911","article-title":"Autoimmune hepatitis: Appraisal of current treatment guidelines","volume":"10","author":"Lowe","year":"2018","journal-title":"World J. Hepatol."},{"key":"B85","first-page":"397","article-title":"Guidelines for the diagnosis and management of drug-induced liver injury in China (2023 edition) [in Chinese]","volume":"28","author":"Ma","year":"2023","journal-title":"Chin. J. Gastroenterology"},{"key":"B86","doi-asserted-by":"publisher","first-page":"S83","DOI":"10.1097\/01.mcg.0000155548.91524.6e","article-title":"Drug-Induced hepatotoxicity: 2005","volume":"39","author":"Maddrey","year":"2005","journal-title":"J. Clin. Gastroenterol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.2169\/internalmedicine.47.1080","article-title":"Pseudoaldosteronism caused by combined administration of cilostazol and glycyrrhizin","volume":"47","author":"Maeda","year":"2008","journal-title":"Intern Med."},{"key":"B88","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s11418-021-01484-3","article-title":"Exploration for the real causative agents of licorice-induced pseudoaldosteronism","volume":"75","author":"Makino","year":"2021","journal-title":"J. Nat. Med."},{"key":"B89","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3937\/kampomed.66.197","article-title":"Literature survey on the frequency of pseudohyperaldosteronism related to licorice usage","volume":"66","author":"Manya","year":"2015","journal-title":"Jpn. J. Orient. Med."},{"key":"B90","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3760\/cma.j.cn501113-20230829-00077","article-title":"Interpretation of the Chinese guideline for diagnosis and management of drug-induced liver injury (2023 version)","volume":"32","author":"Mao","year":"2024","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"B91","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1097\/AOG.0000000000005585","article-title":"Drug-Induced liver injury in pregnancy: the U.S. drug-induced liver injury network experience","volume":"143","author":"Masood","year":"2024","journal-title":"Obstet. Gynecol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"100157","DOI":"10.1016\/j.mtbio.2021.100157","article-title":"miR122-Controlled all-in-one nanoplatform for in situ theranostic of drug-induced liver injury by visualization imaging guided on-Demand drug release","volume":"12","author":"Meng","year":"2021","journal-title":"Mater Today Bio"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1210\/endo-125-2-1046","article-title":"Licorice inhibits corticosteroid 11 beta-dehydrogenase of rat kidney and liver: in vivo and in vitro studies","volume":"125","author":"Monder","year":"1989","journal-title":"Endocrinology"},{"key":"B94","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1620\/tjem.162.183","article-title":"Effects of glycyrrhizin (SNMC: stronger neo-minophagen C) in hemophilia patients with HIV-1 infection","volume":"162","author":"Mori","year":"1990","journal-title":"Tohoku J. Exp. Med."},{"key":"B95","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/BF00118193","article-title":"Enzyme leakage due to change of membrane permeability of primary cultured rat hepatocytes treated with various hepatotoxins and its prevention by glycyrrhizin","volume":"1","author":"Nakamura","year":"1985","journal-title":"Cell Biol. Toxicol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"8743","DOI":"10.3390\/ijerph19148743","article-title":"Glycyrrhizic acid attenuates pulmonary fibrosis of silicosis by inhibiting the interaction between HMGB1 and BRG1 through PI3K\/Akt\/mTOR pathway","volume":"19","author":"Niu","year":"2022","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"B97","first-page":"256","article-title":"Slow N-Acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity","volume":"4","author":"Ohno","year":"2000","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"B98","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/jhg.2016.53","article-title":"MicroRNAs and liver disease","volume":"62","author":"Otsuka","year":"2017","journal-title":"J. Hum. Genet."},{"key":"B99","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1186\/s40064-015-1600-8","article-title":"Clinical features and outcomes of drug-induced liver injury in hospitalized patients in a Chinese tertiary care hospital","volume":"4","author":"Ou","year":"2015","journal-title":"Springerplus"},{"key":"B100","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s41575-023-00771-6","article-title":"Gut-Liver axis: barriers and functional circuits","volume":"20","author":"Pabst","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"961","DOI":"10.3390\/antiox11050961","article-title":"18\u03b2-Glycyrrhetinic acid protects against cholestatic liver injury in bile duct-ligated rats","volume":"11","author":"Pan","year":"2022","journal-title":"Antioxidants (Basel)"},{"key":"B102","doi-asserted-by":"publisher","first-page":"e16454","DOI":"10.7759\/cureus.16454","article-title":"How much is too much? Exploring pseudohyperaldosteronism in glycyrrhizic acid toxicity from chronic licorice root consumption","volume":"13","author":"Patel","year":"2021","journal-title":"Cureus"},{"key":"B103","doi-asserted-by":"publisher","first-page":"484","DOI":"10.3389\/fendo.2019.00484","article-title":"Licorice: from pseudohyperaldosteronism to therapeutic uses","volume":"10","author":"Sabbadin","year":"2019","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B104","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/hep4.1503","article-title":"Drug-Induced liver injury in GI practice","volume":"4","author":"Sandhu","year":"2020","journal-title":"Hepatol. Commun."},{"key":"B105","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","article-title":"An official ATS statement: hepatotoxicity of antituberculosis therapy","volume":"174","author":"Saukkonen","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B106","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1042\/BJ20082416","article-title":"Glycyrrhizin, the main active compound in liquorice, attenuates pro-Inflammatory responses by interfering with membrane-dependent receptor signalling","volume":"421","author":"Schr\u00f6felbauer","year":"2009","journal-title":"Biochem. J."},{"key":"B107","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.ijpharm.2019.01.047","article-title":"Glycyrrhizic acid as a multifunctional drug carrier - from physicochemical properties to biomedical applications: a modern insight on the ancient drug","volume":"559","author":"Selyutina","year":"2019","journal-title":"Int. J. Pharm."},{"key":"B108","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1053\/j.gastro.2019.02.002","article-title":"Incidence and etiology of drug-induced liver injury in mainland China","volume":"156","author":"Shen","year":"2019","journal-title":"Gastroenterology"},{"key":"B109","doi-asserted-by":"publisher","first-page":"822154","DOI":"10.3389\/fphar.2021.822154","article-title":"Transcriptome and lipid metabolomics-based discovery: Glycyrrhizic acid alleviates tripterygium glycoside tablet-induced acute liver injury by regulating the activities of CYP and the metabolism of phosphoglycerides","volume":"12","author":"Shi","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B110","first-page":"58","article-title":"Indications for and technique of trabeculectomy (trabeculocanalectomy)","author":"Shmeleva","year":"1974","journal-title":"Vestn. Oftalmol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"934","DOI":"10.5588\/ijtld.12.0782","article-title":"Hepatotoxicity due to first-line anti-tuberculosis drugs: a five-year experience in a Taiwan medical centre","volume":"17","author":"Shu","year":"2013","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"B112","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1055\/a-2097-0531","article-title":"Genetic and epigenetic basis of drug-induced liver injury","volume":"43","author":"Singh","year":"2023","journal-title":"Semin. Liver Dis."},{"key":"B113","first-page":"24","article-title":"Jianmin Prevention and management measures of pseudohyperaldosteronism induced by compound glycyrrhizin [in Chinese]","volume":"12","author":"Song","year":"2015","journal-title":"J. North Pharm."},{"key":"B114","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cld.2019.08.003","article-title":"Genetic predisposition to drug-induced liver injury","volume":"24","author":"Stephens","year":"2020","journal-title":"Clin. Liver Dis."},{"key":"B115","first-page":"810","article-title":"Diagnosis and treatment guideline on drug-induced liver injury","volume":"23","year":"2015","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"B116","doi-asserted-by":"publisher","first-page":"826","DOI":"10.2174\/1389557519666190119111125","article-title":"Research progress of glycyrrhizic acid on antiviral activity","volume":"19","author":"Sun","year":"2019","journal-title":"Mini Rev. Med. Chem."},{"key":"B117","doi-asserted-by":"publisher","first-page":"e16146","DOI":"10.1111\/liv.16146","article-title":"MinjunChen, null epidemiology and risk determinants of drug-induced liver injury: current knowledge and future research needs","volume":"45","author":"Suzuki","year":"2025","journal-title":"Liver Int."},{"key":"B118","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1053\/j.gastro.2014.10.042","article-title":"Gut-Liver axis in alcoholic liver disease","volume":"148","author":"Szabo","year":"2015","journal-title":"Gastroenterology"},{"key":"B119","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.cyto.2006.10.002","article-title":"Glycyrrhizin inhibits the manifestations of anti-inflammatory responses that appear in association with systemic inflammatory response syndrome (SIRS)-like reactions","volume":"35","author":"Takei","year":"2006","journal-title":"Cytokine"},{"key":"B120","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.3390\/cimb46020078","article-title":"Gut-Liver axis as a therapeutic target for drug-induced liver injury","volume":"46","author":"Tao","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3760\/cma.j.cn501113-20230419-00176-1","article-title":"Study group of drug-induced liver disease, Chinese medical association for the study of liver diseases [Chinese guideline for diagnosis and management of drug-induced liver injury (2023 version)]","volume":"31","year":"2023","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"B122","doi-asserted-by":"publisher","first-page":"4828","DOI":"10.3390\/ijms23094828","article-title":"Liver injury in COVID-19 patients with drugs as causatives: a systematic review of 996 DILI cases published 2020\/2021 based on RUCAM as causality assessment method","volume":"23","author":"Teschke","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B123","doi-asserted-by":"publisher","first-page":"e051484","DOI":"10.1136\/bmjopen-2021-051484","article-title":"Clinical efficacy and security of glycyrrhizic acid preparation in the treatment of Anti-SARS-CoV-2 drug-induced liver injury: a protocol of systematic review and meta-analysis","volume":"11","author":"Tian","year":"2021","journal-title":"BMJ Open"},{"key":"B124","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/j.cmet.2022.09.017","article-title":"Gut-Liver axis: pathophysiological concepts and clinical implications","volume":"34","author":"Tilg","year":"2022","journal-title":"Cell Metab."},{"key":"B125","doi-asserted-by":"publisher","first-page":"5082","DOI":"10.4049\/jimmunol.179.8.5082","article-title":"Modulation of miR-155 and miR-125b levels following Lipopolysaccharide\/TNF-Alpha stimulation and their possible roles in regulating the response to endotoxin shock","volume":"179","author":"Tili","year":"2007","journal-title":"J. Immunol."},{"key":"B126","doi-asserted-by":"publisher","first-page":"837","DOI":"10.3389\/fphar.2019.00837","article-title":"Mechanistic studies of idiosyncratic DILI: clinical implications","volume":"10","author":"Uetrecht","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1080\/17425255.2025.2495955","article-title":"DILI prediction in drug development: present and future","volume":"21","author":"Uetrecht","year":"2025","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1055\/s-0034-1375954","article-title":"Genetic basis of drug-induced liver injury: present and future","volume":"34","author":"Urban","year":"2014","journal-title":"Semin. Liver Dis."},{"key":"B129","doi-asserted-by":"publisher","first-page":"390","DOI":"10.3390\/antiox10030390","article-title":"Oxidative stress in drug-induced liver injury (DILI): from mechanisms to biomarkers for use in clinical practice","volume":"10","author":"Villanueva-Paz","year":"2021","journal-title":"Antioxidants (Basel)"},{"key":"B130","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.1016\/j.bmcl.2012.03.081","article-title":"Biological evaluation and structure-activity relationships of glycyrrhetinic acid derivatives as novel anti-hepatitis B virus agents","volume":"22","author":"Wang","year":"2012","journal-title":"Bioorg Med. Chem. Lett."},{"key":"B131","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.tox.2017.05.012","article-title":"Glycyrrhizin and glycyrrhetinic acid inhibits alpha-naphthyl isothiocyanate-induced liver injury and bile acid cycle disruption","volume":"386","author":"Wang","year":"","journal-title":"Toxicology"},{"key":"B132","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1097\/HJH.0000000000001201","article-title":"Apparent mineralocorticoid excess caused by a novel mutation in 11\u03b2-Hydroxysteroid dehydrogenase type 2 gene","volume":"35","author":"Wang","year":"","journal-title":"J. Hypertens."},{"key":"B133","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1111\/liv.14204","article-title":"Efficacy and safety of magnesium isoglycyrrhizinate injection in patients with acute drug-induced liver injury: a phase II trial","volume":"39","author":"Wang","year":"2019","journal-title":"Liver Int."},{"key":"B134","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.3390\/metabo12111128","article-title":"Glycyrrhizic acid mitigates tripterygium-glycoside-tablet-induced acute liver injury via PKM2 regulated oxidative stress","volume":"12","author":"Wang","year":"","journal-title":"Metabolites"},{"key":"B135","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1111\/apt.16902","article-title":"Corticosteroid plus glycyrrhizin therapy for chronic Drug- or herb-induced liver injury achieves biochemical and histological improvements: a randomised open-label trial","volume":"55","author":"Wang","year":"","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B136","doi-asserted-by":"publisher","first-page":"155878","DOI":"10.1016\/j.phymed.2024.155878","article-title":"Glycyrrhizic acid ameliorates hepatic fibrosis by inhibiting oxidative stress via AKR7A2","volume":"133","author":"Wang","year":"2024","journal-title":"Phytomedicine"},{"key":"B137","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1002\/cpt.2108","article-title":"Clinical characteristics and outcome of drug-induced liver injury in the older patients: from the young-old to the oldest-old","volume":"109","author":"Weersink","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"B138","doi-asserted-by":"publisher","first-page":"214","DOI":"10.3760\/cma.j.cn501113-20240201-00072","article-title":"An analysis on clinical characteristics and prognosis-related risk factors in patients with drug-induced liver injury","volume":"32","author":"Wei","year":"2024","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"B139","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.brainresbull.2020.08.008","article-title":"Glycyrrhizic acid protects juvenile epileptic rats against hippocampal damage through activation of Sirtuin3","volume":"164","author":"Wu","year":"2020","journal-title":"Brain Res. Bull."},{"key":"B140","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41401-020-0383-9","article-title":"Research progress on the protective effects of licorice-derived 18\u03b2-Glycyrrhetinic acid against liver injury","volume":"42","author":"Wu","year":"2021","journal-title":"Acta Pharmacol. Sin."},{"key":"B141","doi-asserted-by":"publisher","first-page":"tfaf024","DOI":"10.1093\/toxres\/tfaf024","article-title":"Magnesium isoglycyrrhizinate prevented the liver injury of acetaminophen by promoting mitochondrial biogenesis","volume":"14","author":"Xia","year":"2025","journal-title":"Toxicol. Res. (Camb)"},{"key":"B142","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/S1875-5364(24)60685-0","article-title":"Glycyrrhizic acid-based multifunctional nanoplatform for tumor microenvironment regulation","volume":"22","author":"Xiao","year":"2024","journal-title":"Chin. J. Nat. Med."},{"key":"B143","first-page":"386","article-title":"Changes in serum miR-122, IL-1\u03b2, and IL-10 levels in patients with drug-induced liver injury and their clinical significance [in Chinese]","volume":"28","author":"Xiong","year":"2025","journal-title":"J. Pract. Hepatology"},{"key":"B144","doi-asserted-by":"publisher","first-page":"e114049","DOI":"10.1371\/journal.pone.0114049","article-title":"A semi-physiologically based pharmacokinetic pharmacodynamic model for glycyrrhizin-induced pseudoaldosteronism and prediction of the dose limit causing hypokalemia in a virtual elderly population","volume":"9","author":"Xu","year":"2014","journal-title":"PLoS One"},{"key":"B145","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1124\/dmd.118.082008","article-title":"Glycyrrhizin alleviates nonalcoholic steatohepatitis via modulating bile acids and meta-inflammation","volume":"46","author":"Yan","year":"2018","journal-title":"Drug Metab. Dispos."},{"key":"B146","first-page":"321","article-title":"Effects of 18 alpha-glycyrrhizic acid on rat liver cytochrome P450 isoenzymes and phase II transferase","volume":"36","author":"Yang","year":"2001","journal-title":"Yao Xue Xue Bao"},{"key":"B147","first-page":"326","article-title":"Meta-analysis of the efficacy and safety of glycyrrhizic acid preparations in the treatment of anti-tuberculosis drug-induced liver injury","volume":"38","author":"Yang","year":"2025","journal-title":"Infect. Dis. Inf."},{"key":"B148","doi-asserted-by":"publisher","first-page":"719197","DOI":"10.3389\/fnut.2021.719197","article-title":"Clinical risk factors of licorice-induced pseudoaldosteronism based on glycyrrhizin-metabolite concentrations: a narrative review","volume":"8","author":"Yoshino","year":"2021","journal-title":"Front. Nutr."},{"key":"B149","doi-asserted-by":"publisher","first-page":"478","DOI":"10.13748\/j.cnki.issn1007-7693.2019.04.020","article-title":"Systematic review of efficacy and safety of diammonium glycyrrhizinate preparations in the treatment of drug-induced liver injury","volume":"36","author":"Yu","year":"2019","journal-title":"Chin. J. Mod. Appl. Pharm."},{"key":"B150","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1007\/s12072-024-10679-1","article-title":"Age-related differences in drug-induced liver injury: a retrospective single-center study from a large liver disease specialty hospital in China, 2002-2022","volume":"18","author":"Yu","year":"","journal-title":"Hepatol. Int."},{"key":"B151","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11481-024-10128-8","article-title":"Glycyrrhizic acid alleviates semen strychni-induced neurotoxicity through the inhibition of HMGB1 phosphorylation and inflammatory responses","volume":"19","author":"Yu","year":"","journal-title":"J. Neuroimmune Pharmacol."},{"key":"B152","doi-asserted-by":"publisher","first-page":"4023","DOI":"10.3390\/ijms26094023","article-title":"Research progress on the mechanism of bile acids and their receptors in depression","volume":"26","author":"Zhao","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"B153","first-page":"2976","article-title":"Effects of compound glycyrrhizin on the cell cycle of epidermal cells in psoriasis vulgaris via regulating miR-155","volume":"37","author":"Zeng","year":"2021","journal-title":"Chin. J. Immunol."},{"key":"B154","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1111\/bcp.13722","article-title":"The association between the NAT2 genetic polymorphisms and risk of DILI during Anti-TB treatment: a systematic review and meta-analysis","volume":"84","author":"Zhang","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B155","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s00204-019-02595-3","article-title":"Risk profiling using metabolomic characteristics for susceptible individuals of drug-induced liver injury caused by Polygonum multiflorum","volume":"94","author":"Zhang","year":"2020","journal-title":"Arch. Toxicol."},{"key":"B156","doi-asserted-by":"publisher","first-page":"126707","DOI":"10.1016\/j.jhazmat.2021.126707","article-title":"Gut microbiota exaggerates Triclosan-Induced liver injury via gut-liver axis","volume":"421","author":"Zhang","year":"2022","journal-title":"J. Hazard Mater"},{"key":"B157","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3390\/cimb46010019","article-title":"Integrating metabolomics and network pharmacology to decipher the hepatoprotective effect mechanisms of magnesium isoglycyrrhizinate injection","volume":"46","author":"Zhang","year":"2023","journal-title":"Curr. Issues Mol. Biol."},{"key":"B158","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.3760\/cma.j.cn112147-20240614-00338","article-title":"Chinese medical association tuberculosis branch [Guidelines for diagnosis and management of drug-induced liver injury caused by anti-tuberculosis drugs (2024 version)]","volume":"47","author":"Zhonghua","year":"2024"},{"key":"B159","doi-asserted-by":"publisher","first-page":"17008","DOI":"10.1038\/cddiscovery.2017.8","article-title":"HMGB1 release by H2O2-Induced hepatocytes is regulated through calcium overload and 58-F interference","volume":"3","author":"Zhao","year":"2017","journal-title":"Cell Death Discov."},{"key":"B160","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ijbiomac.2020.11.204","article-title":"Glycyrrhizin mediated liver-targeted alginate nanogels delivers quercetin to relieve acute liver failure","volume":"168","author":"Zhao","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"B161","doi-asserted-by":"publisher","first-page":"631206","DOI":"10.3389\/fphar.2021.631206","article-title":"Glycyrrhizic acid for COVID-19: findings of targeting pivotal inflammatory pathways triggered by SARS-CoV-2","volume":"12","author":"Zheng","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B162","first-page":"36","article-title":"Clinical effect observation of magnesium isoglycyrrhizinate combined with reduced glutathione in the treatment of drug-induced liver injury in the elderly [in Chinese]","volume":"9","author":"Zhou","year":"2016","journal-title":"Chin. J. New Clin. Med."},{"key":"B163","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1080\/21655979.2021.1937445","article-title":"Glycyrrhizic acid alleviates the meconium-induced acute lung injury in neonatal rats by inhibiting oxidative stress through mediating the Keap1\/Nrf2\/HO-1 signal pathway","volume":"12","author":"Zhu","year":"2021","journal-title":"Bioengineered"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1890794\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T07:19:13Z","timestamp":1786346353000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1890794\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":163,"alternative-id":["10.3389\/fphar.2026.1890794"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1890794","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]},"article-number":"1890794"}}